Here is your cheat sheet to all therapeutic options that were cleared by the FDA in September 2026 spanning tumor types.
Commentary|Videos|August 4, 2025
Molecular Testing in Lung Cancer: Personalized Diagnostics Are Transforming Care
Author(s)Luis E Raez, MD, FASCO, FACP
Luis E. Raez, MD, FACP, FASCO, dives into evolving practices in molecular testing for patients with lung cancer.
Advertisement
Luis E. Raez, MD, FACP, FASCO, dives into the evolving use of molecular testing for patients with lung cancer. Raez is the medical director of Memorial Cancer Institute, oncology research director of Memorial Health Care System, and director of the Thoracic Oncology Program at the Florida Society of Clinical Oncology. He is also a clinical associate professor of medicine at Florida International University and a visiting professor of medicine at Cayetano Heredia University in Peru.
Advertisement
Related to this article
TRE-515 earned fast track status in combination with KRAS inhibitors for G12C-mutated NSCLC after anti–PD-(L)1 therapy and platinum-based chemotherapy.
An NDA for zipalertinib in EGFR exon 20 insertion–positive NSCLC is being supported by phase 3 REZILIENT3 data.
The liquid biopsy identifies ESR1 mutations in blood to select patients with metastatic breast cancer who may be eligible for treatment with camizestrant.
Natera’s blood-based, cell-free DNA multi-cancer early detection assay received the designation after the FDA reviewed data spanning 12 cancer types.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Experts break down key lung cancer data and trends from the IASLC 2026 World Conference on Lung Cancer.
The c-Met–directed ADC was designated for EGFR wild-type nonsquamous NSCLC after platinum chemotherapy and anti–PD-(L)1 therapy.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Breakthrough Device Designation to Natera’s Multi-Cancer Early Detection Assay
2
Targeted Approaches in Pancreatic Cancer, Chemo Intensification in CRC Take Center Stage as Key GI Oncology Presentations at ESMO 2026
3
FDA Approves Atezolizumab Plus Chemo for Stage III dMMR Colon Cancer
4
Next-Generation NAMPT Inhibitors Aim to Revive a Stalled Target in AML and MDS
5